Childhood psoriasis: Analytic retrospective study in Saudi patients
|
|
- Lizbeth Fitzgerald
- 5 years ago
- Views:
Transcription
1 Journal of the Saudi Society of Dermatology & Dermatologic Surgery (2011) 15, King Saud University Journal of the Saudi Society of Dermatology & Dermatologic Surgery ORIGINAL ARTICLE Childhood psoriasis: Analytic retrospective study in Saudi patients Sami N. Alsuwaidan * Department of Dermatology, Psoriasis Research Chair, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Riyadh, Saudi Arabia Received 20 December 2010; accepted 20 February 2011 Available online 20 May 2011 KEYWORDS Psoriasis; Guideline; Saudi Abstract Psoriasis is a genetically determined chronic inflammatory and immunologically mediated disease. At an early age, the presentation of psoriasis may be atypical. Among all types of childhood psoriasis, plaque type is the most common. In this article, we report our data analysis on the main clinical aspects of childhood psoriasis, its onset, risk factors, demographics and therapeutic options. A total of 36 patients with childhood psoriasis were evaluated at the dermatology out-patient clinic in the college of medicine at King Saud University during the period from April 2002 to June All patients were diagnosed based on clinical findings. Of the 36 patients, 24 (66.67%) had generalized plaque type psoriasis, 8 (22.2%) had guttate psoriasis, 4 (11.1%) had mixed plaque type and guttate psoriasis, 6 (16.67%) had localized plaque type (on elbows and knees), 4 (11.11%) had palmoplanter psoriasis and 1 (2.77%) had scalp psoriasis. Among those, one patient had congenital psoriasis. The age of patients ranged from 8 months to 18 years (mean = 11.3 years). There were 15 males and 21 females. The mean duration of the disease was 3.04 years and family history was positive in 10 patients (27.78%). All patients were treated by topical medications and/or narrow-band ultraviolet-b phototherapy. Apart from prolonged tanning no significant adverse effects were reported. Of particular interest, skin cancer was not detected in this series of children even after repeated courses. In conclusion, childhood psoriasis is more common in girls with plaque type psoriasis being the most common type. Topical therapy is the mainstay treatment for localized disease and narrow-band ultraviolet-b phototherapy is considered safe and effective for moderately severe conditions. More studies are required to define the safety of systemic therapy and biologic treatment in this age group of psoriasis. ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved. * Tel.: ; fax: address: salsuwaidan@ksu.edu.sa X ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved. Peer review under responsibility of King Saud University. doi: /j.jssdds Production and hosting by Elsevier 1. Introduction Psoriasis is a genetically determined chronic inflammatory disorder seen in 3.5% of US population (Kurd and Gelfand, 2009). The incidence in Saudi Arabia has not been precisely defined. It is mainly classified into two age groups: childhood psoriasis that develops below the age of 18 years and adulthood psoriasis that develops after the age of 18 years. Childhood psoriasis is broadly sub-classified into three age groups:
2 58 S.N. Alsuwaidan infantile psoriasis (onset within the first year of age), pediatric psoriasis and pediatric psoriasis with psoriatic arthritis (Silverberg, 2009). Moreover, Congenital psoriasis (psoriasis since birth), a distinct entity of psoriasis associated with lower prevalence of family history, different pattern of anatomic involvement, higher fraction of erythrodermic, pustular or linear subtypes and poor prognosis has been described. It has been suggested that congenital psoriasis should be considered in the category of erythematous, scaly, or pustular eruptions in the newborn (Lehman and Rahil, 2008). The aim of this article is to look over the clinical aspects, risk factors and therapeutic options of childhood psoriasis in Saudi patients. 2. Demographics and onset of the disease In this study a total of 36 patients with childhood psoriasis were evaluated at the dermatology out-patient clinic in the college of medicine at King Saud University during the period from April 2002 to June The age of patients ranged from 8 months to 18 years (mean = 11.3 years). The mean duration of disease was 3.04 years. Male patients were 15 (41.67%) and females were 21 (51.33%) (see Table 1). The incidence of childhood psoriasis is unknown (Marcoux and Prost, 2002), but it has been reported that 10% of all cases occurred before the age of 10 years and 2% at less than 2 years of age (Burden, 1999). The differences of the onset between females and males have varied from region to region (Morris et al., 2001). In a study from India, the age of onset of the disease ranged from 4 days to 14 years. The mean age of onset in boys was 8.1 ± 2.1 years and in girls was 9.3 ± 2.3 years. (Kumar et al., 2004). In another report from china, a study was carried out in 277 childhood psoriatic patients where the mean age of onset was found to be 11 years. The male: female ratio was 1:1.13. The median age of onset of disease was 10 years (Fan et al., 2007). Furthermore, a population based study was performed in USA to assess the incidence of childhood psoriasis which revealed that the annual incidence was 40.8 per 100,000. Authors concluded that the incidence of pediatric psoriasis increased with age and both males and females suffer equally (Tollefson et al., 2010). In a retrospective analysis from Turkey, 61 children with psoriasis under age of 18 years were evaluated. Twenty three (37.70%) were males and 38 (62.30%) were females. The mean age of patients was 9.28 ± 4.02% for females and ± 3.85% for males. The mean age of onset of the disease in females was 6.81 ± 4.11 years and 7.03 ± 4.28 years in males (Seyhan et al., 2006). the triggering factors were respiratory tract infections (14.8%) and positive throat culture for group A-beta hemolytic streptococci (21.3%). Also, the frequency of emotional stress and psychiatric morbidity was 54% and 9.8%, respectively. It is suggested that stress and upper respiratory tract infections are the most important triggering factors in childhood and adult psoriasis. They also reported a positive family history in 14 cases (23%) (Seyhan et al., 2006). Apart from positive family history in one third of our patients, we did not find any other significant associated factors. This might be explained by the small number of patients in our study. 4. Clinical patterns In our study, all patients were diagnosed based on clinical findings. Of the 36 patients, 24 (66.67%) had generalized plaque type psoriasis, 8 (22.2%) had guttate psoriasis, 4 (11.1%) had mixed plaque type and guttate psoriasis (see Fig. 1), 6 (16.67%) had localized plaque type (on elbows and knees), 4 (11.11%) had palmoplanter psoriasis and 1 (2.77%) had scalp psoriasis. Among those, one patient had congenital psoriasis (see Table 1). Most children with psoriasis manifest with the plaque type disease (68.6%) in similar patterns to adult patients, with lesions being localized to the scalp, post auricular region, elbows, and knees. Guttate disease is more common in pediatric than in adult patients. It was present in 28.9% of 277 children in a Chinese survey. Other patterns in childhood psoriasis include erythroderma (1.4%), pustular disease including palmoplantar pustular psoriasis (1.1%), and mucosal glossitis (1.1%) (Fan et al., 2007). Another study has shown that the most frequent clinical type of childhood psoriasis is plaque type in 1302 patients (68.1%), followed by guttate psoriasis in 727 patients (38.0%). Erythrodermic psoriasis and pustular psoriasis were only seen in 7.3% and 5.0% of patients, respectively (Jager and Jong, 2010). Though generalized pustular psoriasis in children is uncommon, it may present as a severe and potentially life-threatening disorder. Four clinical patterns of pustular psoriasis have been described in children: generalized pustular psoriasis, annular pustular psoriasis, exanthematous pustular psoriasis, and localized pustular psoriasis. Mixed variants of these patterns are also possible. 3. Risk factors In a recent report, there was no evidence to support that getting affected by psoriasis before the age of 18 years influences disease activity in later life or type of treatments used (Jager and Jong, 2010). The association of childhood obesity and psoriasis is of significance. A study was conducted to observe the influence of obesity on childhood psoriasis, it was concluded that being overweight is an important risk factor for the onset of childhood psoriasis (Boccardi and Menni, 2009). It is suggested that psoriasis should be added to the adverse consequences of childhood obesity (Naldi et al., 1996). Seyhan et al, from Turkey found that in most of their 61 patients Figure 1 Child with mixed guttate and plaque type psoriasis.
3 Childhood psoriasis: Analytic retrospective studyin Saudi patients 59 Generalized pustular psoriasis has been reported in a 6-weekold infant (Chao et al., 2009). In regard to congenital psoriasis, erythrodermic and pustular variants are common presentations (Lehners-Weber et al., 1996; Al-Fouzan et al., 1990; Lerner and Lerner, 1972; Henriksen and Zachariae, 1972). 5. Therapy Topical treatment is the first line therapy in childhood psoriasis for a limited disease. In a more severe disease, systemic therapy and phototherapy are considered to control the disease. Well-designed studies on systemic therapeutic modalities for psoriasis in pediatric age group are meager and children are treated with the support of data extrapolated from those in adults (Burden, 1999). 6. Topical treatment There are various agents frequently used as topical therapies for childhood psoriasis. Topical corticosteroids are usually prescribed. Mild forms of topical corticosteroids are used for the face, whereas, moderate to potent forms are used for the body and scalp. More than 40% of our patients were treated by either topical corticosteroids or calcipotriene. Topical Calcipotriene was proved to be efficacious in childhood psoriasis treatment in 43 children (Oranje et al., 1997). Anthralin 1% is rarely used in childhood psoriasis because of localized irritation (Farber and Nall, 1999). Other topical agents described in the treatment of childhood psoriasis are topical calcineurin inhibitors, tacrolimus 0.3% ointment, and pimecrolimus 1% cream (Stefanakiet al., 2010). 7. Phototherapy Phototherapy is considered a safe and effective treatment for children. Generalized or hand-foot therapy, either narrowband ultraviolet-b (NB-UVB), broadband UVB (BB-UVB) or psoralen and UVA (PUVA) can be used. More than 60% of our patients were treated with NB-UVB and satisfactory results were observed (see Table 1). In one report, 12 weeks treatment with NB-UVB, PASI 90 was achieved in 60% of patients, however, 10% had less than 50% improvement (Jain et al., 2007). A series of 113 children were treated by various phototherapy methods. Positive response was observed in 92.9% of psoriatic patients treated by NB-UVB, in 83.3% of those treated with PUVA and in 93.3% of those treated with BB-UVB (Ersoy- Evans et al., 2008). NB-UVB and PUVA therapies have shown satisfactory results in treating childhood guttate and plaque psoriasis as marked improvement was found in 88% of 25 patients treated with these two modalities (Al-fouzan and Nanda, 1995). In another study conducted on 35 patients of childhood psoriasis, clearance of disease was found in 63% of cases (Jury et al., 2006). Only few cases are reported to develop erythema and anxiety during phototherapy, otherwise, treatment is being well tolerated (Tay et al., 1996). From our experience, phototherapy is considered safe and effective treatment of childhood psoriasis where NB-UVB is favored over PUVA due to increased safety profile and convenience for patients. During Phototherapy, Our patients encountered tanning effect, pruritus and dryness that might be aggravated by local climate nature. In our data no single case of skin cancer was reported over 10 year experience with phototherapy. Although phototherapy is a simple, safe and effective treatment, both children and their parents must be educated for the possible adverse effects and the associated hazards of overexposure. 8. Oral antibiotics Multiple studies implicate subclinical or recurrent streptococcal infection as a trigger or maintenance factor in the pathogenesis of psoriasis in children. In one study reviewing studies and reports examining this particular relationship concluded that the percentage of psoriasis patients who experienced disease clearance with antibiotic therapy ranged from 0% to 55%, with no patients experiencing disease worsening during treatment. The available evidence does not demonstrate the efficacy of antibiotic therapy in the treatment of childhood psoriasis. Because these treatments are relatively benign compared to other treatments for severe psoriasis, the use of antibiotic therapy may still be worth considering, especially for those patients with recurrent streptococcal infections that seem to trigger or maintain their skin disease (Wilson et al., 2003). A controlled study revealed mixed results of oral antibiotics therapy in childhood psoriasis (Dogan et al., 2008). In our experience the response to oral antibiotics in children with psoriasis was variable with majority being none responsive. 9. Systemic treatment Systemic treatment is the ultimate option in severe and uncontrolled cases. Systemic therapeutic options may include cyclosporine (Cordoro, 2008; Mahe et al., 2001), systemic retinoids (Davis and Krafchik, 1993; Rosinska et al., 1988) and methotrexate (Collin et al., 2006; Kumar et al., 1994). Limited resources and studies are available to assess appropriately the efficacy and safety of these treatments in childhood psoriasis. We have not tried such modalities in our series and no further comments can be made. 10. Biologics The biologic therapy namely Tumor Necrosis Factor-alpha (TNF-alpha) blockers like etanercept and infliximab has been used recently in pediatric auto immune diseases like rheumatoid arthritis, TNF-a receptor 1-associated periodic syndrome without fever (TRAPS), juvenile idiopathic arthritis and crohn s disease. Safety and efficacy of etanercept therapy have been recognized in juvenile rheumatoid arthritis patients (Lovell et al., 2008). In a placebo-controlled randomized double-blind trial, 211 children with plaque psoriasis were treated with once-weekly subcutaneous injections of etanercept (0.8 mg/kg), with a maximum dose of 50 mg. At week 12, 27% of patients treated with etanercept reached PASI 90, in contrast to 7% of patients treated with placebo (Paller et al., 2008). Further reports manifest the positive response of etanercept (Safa et al., 2007; Papoutsaki et al., 2006). In one case report one child with psoriasis was successfully treated with Infliximab after failure of etanercept (Farnsworth et al., 2005). We did not use these drugs in our patients at this stage. But we stress that these drugs cannot be used frequently until more data are available about the risk-benefit ratio of these treatments in childhood psoriasis. With future studies proper
4 60 S.N. Alsuwaidan Table 1 Childhood psoriasis: patients series of 36 patients. Serial No. Age (yr) Sex Duration of disease (yr) Pattern of the disease Family history Mode of treatment 1 7 f 4 Generalized (plaque type) Negative NB-UVB 2 7 f 2 Generalized (plaque type) Positive NB-UVB 3 11 f 2 Guttate type Positive NB-UVB 4 6 m 1 Mixed guttate and plaque Negative NB-UVB 5 7 m 2 Generalized (plaque type) Negative NB-UVB/Corticosteroids 6 12 f 1 Guttate type Negative NB-UVB 7 11 f 2 Mixed guttate and plaque Negative NB-UVB 8 10 f 1.5 Localized e/k (plaque type) Positive Corticosteroids 9 9 f 4 Localized e/k (plaque type) Negative Calcipotriene f 3 Generalized (plaque type) Positive NB-UVB f 1 Palmoplantar Negative Corticosteroids f 2 Localized e/k (plaque type) Negative Calcipotriene 13 4 m 1.5 Guttate type Negative NB-UVB/oral antibiotic m Since birth Congenital Negative Corticosteroids m 6 Palmoplantar Negative Calcipotriene 16 4 m 1 Guttate type Negative NB-UVB/ oral antibiotic 17 8 f 2 Guttate type Positive NB-UVB f 6 Generalized (plaque type) Negative NB-UVB/Corticosteroids f 6 Mixed guttate and plaque Negative NB-UVB f 0.3 Generalized (plaque type) Negative NB-UVB f 5 Guttate type Negative NB-UVB 22 4 f 1 Scalp psoriasis Negative Corticosteroids m 8 Generalized (plaque type) Negative NB-UVB/Corticosteroids m 4 Localized e/k (plaque type) Negative Calcipotriene m 0.2 Localized e/k (plaque type) Negative Corticosteroids f 6 Palmoplantar Positive Corticosteroids 27 8 f 4 Generalized (plaque type) Negative NB-UVB f 2 Palmoplantar Negative Corticosteroids 29 9 m 2 Guttate type Positive NB-UVB/ oral antibiotic m 5 Generalized (plaque type) Positive NB-UVB m 11 Generalized (plaque type) Positive NB-UVB/Corticosteroids f 0.3 Mixed guttate and plaque Negative NB-UVB 33 6 f 1.5 Generalized (plaque type) Negative NB-UVB m 3 Guttate type Negative NB-UVB m 1.3 Generalized (plaque type) Positive NB-UVB/Corticosteroids m 1 Localized e/k (plaque type) Negative Corticosteroids e/k: Elbows and knees. positioning of biologics in the therapeutic ladder of psoriasis in children might be possible. 11. Conclusion With evaluation of our series of children with psoriasis we conclude that childhood psoriasis is more common in females with plaque type psoriasis being the most common type. Topical therapy is the mainstay treatment for localized disease. At present, NB-UVB phototherapy is a safe and effective modality for moderately severe cases particularly in children with poor response to topical therapeutic protocols. Systemic therapy and biologics should be reserved for severe and uncontrolled cases. More clinical studies are required to define the safety levels of systemic therapies and biologic treatments to properly define their position in the therapeutic ladder of childhood psoriasis. References Al-fouzan, AS., Nanda, A., UVB phototherapy in childhood psoriasis. Pediatr. Dermatol. 12, 66. Al-Fouzan, S.A., Hassab-El-Nabi, H.M.M., Nanda, A., Congenital linear psoriasis: a case report. Pediatr. Dermatol. 7, Boccardi, D., Menni, S., Vecchia, CLA., Nobile, M., Decarli, A., Volpi, G., Ferraroni, M., Br. J. Dermatol. 161, Burden, A.D., Management of psoriasis in childhood. Clin. Exp. Dermatol. 24, Burden, A.D., Management of psoriasis in childhood. Clin. Exp. Dermatol. 24, Chao, P., Cheng, Y., Chung, M., Generalized pustular psoriasis in a 6-week-old infant. Pediatr. Dermatol. 26 (3), Collin, B., Ogboli, M., Moss, C., Methotrexate therapy in 10 children with severe plaque psoriasis: P-29. Br. J. Dermatol. 155 (Suppl), 33. Cordoro, K.M., Systemic and light therapies for the management of childhood psoriasis: part II. Skin Ther. Lett. 13, 1 3. Davis, A., Krafchik, B.R., New drugs in pediatric dermatology. Curr. Opin. Pediatr. 5, Dogan, B., Karabudak, O., Harmanyeri, Y., Antistreptococcal treatment of guttate psoriasis: a controlled study. Int. J. Dermatol. 47, Ersoy-Evans, S., Altaykan, A., Sahin, S., Kolemen, F., Phototherapy in childhood. Clinical and laboratory investigations. Pediatric Dermatol. 25 (6),
5 Childhood psoriasis: Analytic retrospective studyin Saudi patients 61 Fan, X., Xiao, F.L., Yanq, S., Liu, J.B., Yan, K.L., Lianq, Y.H., Sun, L.D., Du, W.H., Jin, Y.T., Zhang, X.J., Childhood psoriasis: a study of 277 patients from China. J. Eur. Acad. Dermatol. Venereol. 6, Farber, E.M., Nall, L., Childhood psoriasis. Cutis 64, Farnsworth, N.N., George, S.J., Hsu, S., Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol. Online J. 11, 11. Henriksen, L., Zachariae, H., Pustular psoriasis and arthritis in congenital psoriasiform erythroderma. Dermatologica 144, de Jager ME, de Jong EM, Meeuwis ka, van de Kerkhof PC, Seyger MM. No evidence found that childhood onset of psoriasis influences disease severity, future body mass index of type of treatments used. JEAVD 2010; (Accepted 5 Feburary). Jain, V.K., Aggarwal, K., Jain, K., et al., Narrow-band UV-B phototherapy in childhood psoriasis. Int. J. Dermatol. 46, Jury, C.S., McHenry, P., Burden, A.D., Lever, R., Bilsland, D., Narrow-band ultraviolet B (UVB) phototherapy in children. Clin. Exp. Dermatol. 31, Kumar, B., Dhar, S., Handa, S., Kaur, I., Methotrexate in childhood psoriasis. Pediatr. Dermatol. 11, Kumar, B., Jain, R., Sandhu, K., Kaur, I., Handa, S., Epidemiology of childhood psoriasis: a study of 419 patients from northern India. Int. J. Dermatol. 43 (9), Kurd, S.K., Gelfand, J.M., The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES J. Am. Acad. Dermatol. 60, Lehman, J.S., Rahil, A.K., Congenital psoriasis: case report and literature review. Pediatr. Dermatol. 25 (3), Lehners-Weber, C., de la Brassinne, M., Dezfoulian, B., et al., Congenital psoriasis following the lines of Blaschko. Pediatr. Dermatol. 13, Lerner, M.R., Lerner, A.B., Congenital psoriasis: report of three cases. Arch. Dermatol. 105, Lovell, D.J., Reiff, A., Ilowite, N.T., et al., Pediatric Rheumatology Collaborative study group. Safety and efficacy of up to 8 years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 58, Mahe, E., Bodemer, C., Pruszkowski, A., Teillac-Hamel, D., de Prost, Y., Cyclosporin in childhood psoriasis. Arch. Dermatol. 137, Marcoux, D., Prost, Y., Pediatric psoriasis revisited. J. Cutan. Med. Surg. 6 (Suppl. 1), Morris, A., Rogers, M., Fischer, G., Williams, K., Childhood psoriasis: a clinical review of 1262 cases. Pediatr. Dermatol. 18, Naldi, I., Parrazini, F., Peli, I., Et al.dietory factors and the risk of psoriasis. Results of an Italian case-control study. Br. J. Dermatol. 134, Oranje, A.P., Marcoux, D., Svensson, A., Prendiville, J., Krafchik, B., Toole, J., Rosenthal, D., Spek, F.B.W., Molin, L., Axelsen, M., Topical calcipotriol in childhood psoriasis. J. Am. Acad. Dermatol. 36, Paller, A.S., Siegfried, E.C., Langley, R.G., Gottlieb, A.B., Pariser, D., Landells, I., et al., Etanercept treatment of children and adolescents with plaque psoriasis. N. Engl. J. Med. 358, Papoutsaki, M., Costanzo, A., Massotta, A., Gramiccia, T., soda, R., Chimenti, S., Etanercept for the treatment of severe childhood psoriasis. Br. J. Dermatol. 154, Rosinska, D., wolska, H., Jablonska, S., Koncha, I., Etretinate in severe psoriasis of children. Pediatr. Dermatol. 5, Safa, G., Loppin, M., Bousser, A.M., Barbarot, S., Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis. J. Am. Acad. Dermatol. 56 (Suppl), S Seyhan, M., Coskun, B.K., Saglam, H., Ozcan, H., Karincaoglu, Y., Psoriasis in childhood and adolescence. Evaluation of demographic and clinical features. Pediatr. Int. 48 (6), Silverberg, N.B., Pediatric psoriasis: an update. Therape. Clin. Risk Manag. 5, Stefanaki C, Lagogiami E, Kontochristopoulos G et al. Psoriasis in children: a retrospective analysis. J Eur Acad Dermatol Venereal (Epub ahead of print). Tay, Y.K., Morelli, J.G., Weston, W.L., Experience with UVB phototherapy in children. Pediatr. Dermatol. 13, Tollefson, M.G., Crowson, C.S., McEvoy, M.T., Kremers, H.M., Incidence of psoriasis in children: a population based study. J. Am. Acad. Dermatol. 62 (6), Wilson, J.K., Al-Suwaidan, S.N., Krowchuk, D., et al., Treatment of psoriasis in children: is there a role of antibiotic therapy and tonsillectomy? Pediatr. Dermatol. 20,
Etanercept: a new option in paediatric plaque psoriasis
: a new option in paediatric plaque psoriasis Steve Chaplin MSc, MRPharmS, Medical Writer, Dr David Atherton MA, MB, BChir, FRCP, Honorary Consultant in Paediatric Dermatology, Great Ormond Street Hospital
More informationPSORIASIS PSORIASIS. Anatomic sites FACTS ABOUT PROSIASIS PSORIASIS 11/16/2017 STIGMATA OF PSORIASIS
PSORIASIS Dr. Sami Alsuwaidan President, Saudi Society of Dermatology & Dermatologic Surgery Associate Professor and Consultant Department of Dermatology, College of Medicine King Saud University PSORIASIS
More informationPsoriasis is a chronic, inflammatory, Prescribing in children
Psoriasis in children: current approaches to management Laura Proudfoot BSc, MRCP, Elisabeth Higgins MA, FRCP and Judy Davids RGN Our series Prescribing in children gives practical advice for successful
More informationAn otherwise healthy 12-year-old
1105 Photo Rounds.finalREV 10/19/05 2:05 PM Page 947 A young girl with scaly skin plaques The patient had numerous thick red plaques on her back and the extensor surfaces of elbows, knees, and forearms
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationIt is estimated that about 26,000 new cases of
Focus on CME at Dalhousie University Set On Soothing Psoriasis A. H. Murray, MD, FRCP(C) Presented at the 76th Annual Dalhousie Refresher Course It is estimated that about 26,000 new cases of psoriasis
More informationA study of treatment modalities in psoriasis in dermatology outpatient department of a tertiary care teaching hospital
Original article A study of treatment modalities in psoriasis in dermatology outpatient department of a tertiary care teaching hospital 1Y Roja Ramani, 2 Benu Panigrahy, 3 Sailenkumar Mishra, 4 BTPS Singh
More informationPsoriasis in Jordan: a single center experience
Psoriasis in Jordan: a single center experience Shefaa Almashagbeh MD *, Deifallah Alsharari MD *, Hayat Khasawneh MD *, Diana Aljammal * MD, Hamzeh Al-housamieh MD* ABSTRACT Objectives: To evaluate the
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationPsoriasis: Causes, Symptoms, And Treatment
Psoriasis: Causes, Symptoms, And Treatment We all know that a healthy immune system is good. But, do you know that an overactive immune system can cause certain conditions like Psoriasis? Read on to find
More informationPsoriasis is a common inflammatory cutaneous
Childhood psoriasis: a study of 137 cases from central China Yan Wu, Yun Lin, Hou-Jun Liu, Chang-Zheng Huang, Ai-Ping Feng, Jia-Wen Li Wuhan, China 260 Background: Childhood psoriasis is common, but it
More informationRetrospective 10 years review of 100 patients with psoriasis in the Kingdom of Saudi Arabia (KSA)
Retrospective 10 years review of 100 patients with psoriasis in the Kingdom of Saudi Arabia (KSA) Ahmed Abdullah Alhumidi King saud university, Riyadh, kingdom of Saudi Arabia Abstract Background: This
More informationOriginal Policy Date
MP 2.01.07 Psoralens with Ultraviolet A (PUVA) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed by consensus/12:2013 Return to Medical Policy
More informationComparison of the efficacy of PUVA versus BBUVB in the treatment of psoriasis vulgaris
IJMAMR 5 (2017) 1-6 ISSN 2053-1834 Comparison of the efficacy of PUVA versus BBUVB in the treatment of psoriasis vulgaris Tran Hau Khang* and Le Huu Doanh National Hospital of Dermatology and Venereology,
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More informationEfficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis
Efficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis T. Shehzad ( Departments of Dermatology Naval Hospital PNS Shifa, Karachi. ) N. R. Dar ( Departments
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationPsoriasiform Dermatitis in Children: Calling in the Troops
Psoriasiform Dermatitis in Children: Calling in the Troops Markus Boos, MD PhD Attending Physician, Dermatology Seattle Children s Hospital Assistant Professor of Pediatrics, University of Washington School
More informationOriginal article Comparative study of psoralen-uvb vs. UVB-alone therapy in the treatment of psoriasis
Original article Comparative study of psoralen-uvb vs. UVB-alone therapy in the treatment of psoriasis Syed Shamsuddin, *Tahir Saeed Haroon Department of Dermatology, Bolan Medical Complex, Quetta * Department
More informationLight Therapy for Psoriasis Protocol Medical Benefit Effective Date Next Review Date Preauthorization Review Dates Preauthorization is required.
Protocol Light Therapy for Psoriasis (20147) Medical Benefit Effective Date: 07/01/16 Next Review Date: 03/18 Preauthorization Yes Review Dates: 03/16, 03/17 Preauthorization is required. The following
More informationRegulatory Status FDA-approved indication: Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Section: Prescription Drugs Effective Date: Oct 1, 2016 Subject: Enbrel Page: 1 of 7 Last Review Date:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psoriasis: the management of psoriasis 1.1 Short title Psoriasis 2 The remit The Department of Health has asked NICE: 'to produce
More informationA Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients
Volume 1, Issue 3 Research Article A Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients Darukarnphut P, Rattanakaemakorn P *, Rajatanavin N Division
More informationPsoriasis. Causes of Psoriasis
Psoriasis Psoriasis is a common, chronic, relapsing/remitting, immune-mediated systemic disease characterized by skin lesions including red, scaly patches, papules, and plaques, which usually itch. The
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationPredicting the Response to Phototherapy for Psoriasis Patients
A*STAR-NHG-NTU Skin Research Grant Joint Workshop 17 October 2015 Predicting the Response to Phototherapy for Psoriasis Patients Is it possible? Dr Eugene Tan Consultant Dermatologist National Skin Centre
More informationUvA-DARE (Digital Academic Repository) Innovative therapies and new targets in psoriasis de Groot, M. Link to publication
UvA-DARE (Digital Academic Repository) Innovative therapies and new targets in psoriasis de Groot, M. Link to publication Citation for published version (APA): de Groot, M. (2011). Innovative therapies
More informationPHARMACY POLICY STATEMENT Ohio Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Ohio Medicaid Enbrel (etanercept) Must use
More informationThis PDF is available for free download from a site hosted by Medknow Publications
Net Study Comparison of clinical efficacy of topical tazarotene.1% cream with topical clobetasol propionate.5% cream in chronic plaque psoriasis: A double-blind, randomized, right-left comparison study
More informationSYSTEMIC THERAPY OF MODERATE AND SEVERE PSORIASIS WITH METHOTREXATE
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 SYSTEMIC THERAPY OF MODERATE AND SEVERE PSORIASIS WITH METHOTREXATE M. FRÎNCU 1 A. OANŢĂ 1 Abstract:
More informationEffects of Acupuncture on Chinese Adult Patients with Psoriatic Arthritis: A Prospective Cohort Study
Effects of Acupuncture on Chinese Adult Patients with Psoriatic Arthritis: A Prospective Cohort Study Peiyi Chen 1, Tiantian Xin 2* and Yingchun Zeng 3,4 1 School of Nursing, Guangzhou University of Chinese
More informationCOMPARATIVE STUDY OF THE EFFICACY OF VARIOUS TOPICAL TREATMENT MODALITIES AND PHOTOTHERAPY FOR PSORIASIS VULGARIS: A REVIEW
COMPARATIVE STUDY OF THE EFFICACY OF VARIOUS TOPICAL TREATMENT MODALITIES AND PHOTOTHERAPY FOR PSORIASIS VULGARIS: A REVIEW Dr. Shweta Aryal *, Prof. Dr. Liu Jin Xian, Dr. Gong Shao Zhi and Dr. Jyoti Karki
More informationPsoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato
Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema
More informationCOMMON SKIN CONDITIONS IN PRIMARY CARE. Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio
COMMON SKIN CONDITIONS IN PRIMARY CARE Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio DISCLOSURE The Speaker and members of the planning committee do not have a conflict of interest
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationPravit Asawanonda, MD, DSc, and Yaowalak Nateetongrungsak, MD Bangkok, Thailand
Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: A randomized, placebo-controlled study Pravit Asawanonda, MD, DSc, and
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationOriginal Policy Date
MP 2.01.58 Light Therapy for Vitiligo Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return to Medical Policy
More informationSupplementary Tables. Psoriasis a
Supplementary Tables Supplementary Table S1 Age-sex distribution of patients with psoriasis and PPP subdivided by the department specified in a claim with a diagnosis code of psoriasis and PPP in Japanese
More informationPhototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])
Origination: 09/27/07 Revised: 08/2/17 Annual Review: 11/2/17 Purpose: To provide Phototherapy and Photochemotherapy Treatment (PUVA and UBV) guidelines for the Medical Department staff to reference when
More informationFollow this and additional works at: Part of the Skin and Connective Tissue Diseases Commons
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is the Addition of a Topical Agent to
More informationPsoriasis. What is Psoriasis? What causes psoriasis? Medical Topics Psoriasis
1 Psoriasis What is Psoriasis? Psoriasis is a long standing inflammatory non-contagious skin disease which waxes and wanes with triggering factors. There is a genetic predisposition in psoriasis. Internationally,
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
More informationKEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.
KEY MESSAGES Psoriasis is a genetically determined, systemic immune-mediated chronic inflammatory disease that affects primarily the skin and joints. Psoriasis Vulgaris is characterised by well-demarcated
More informationDifference Between Seborrheic Dermatitis and Psoriasis
Difference Between Seborrheic Dermatitis and Psoriasis www.differencebetween.com Key Difference Seborrheic Dermatitis vs Psoriasis Dermatological conditions are perhaps the most worrisome diseases in the
More informationCombination Nonbiologic Therapy in Psoriasis. Sushil Tahiliani, MBBS, MD
Combination Nonbiologic Therapy in Psoriasis Sushil Tahiliani, MBBS, MD Agenda Rationale Preferred and less preferred combination Morphology-specific preferred combinations Doses used in combinations Potential
More informationPsoriasis: Therapeutic goals
Psoriasis: Therapeutic goals I want to die 50 45 impetiginization infliximab 600 40 35 30 400 25 20 15 200 10 5 0 22-ene 21-feb 23-mar 22-abr 22- may Efalizumab 6 doses: flare + REBOUND CSA 3 21-jun 21-jul
More informationMedical Policy. MP Light Therapy for Psoriasis
Medical Policy MP 2.01.47 BCBSA Ref. Policy: 2.01.47 Last Review: 12/27/2017 Effective Date: 12/27/2017 Section: Medicine Related Policies 2.01.44 Dermatologic Applications of Photodynamic Therapy 2.01.86
More informationLight Therapy for Psoriasis. Description
Subject: Light Therapy for Psoriasis Page: 1 of 11 Last Review Status/Date: June 2015 Light Therapy for Psoriasis Description Light therapy for psoriasis includes both targeted phototherapy and photochemotherapy
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 May 2009 STELARA 45 mg, solution for injection B/1 x 0.5 ml vial (CIP code: 392 586-2) JANSSEN-CILAG Ustekinumab
More informationPrior Authorization Conditions for Approval of Enbrel (etanercept) Website Form Submit request via: Fax
Prior Authorization Conditions for Approval of Enbrel (etanercept) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Enbrel (etanercept) require a prior
More informationRecalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University
Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,
More informationADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationThe Treatment Toolbox for Severe Pediatric Psoriasis
The Treatment Toolbox for Severe Pediatric Psoriasis Dr. Kim A. Papp, MD, PhD, FRCPC, FAAD K Papp Clinical Research and Probity Medical Research Objectives: Treating severe pediatric psoriasis 1. Challenges
More informationPhototherapy with Narrow-Band UVB in Adult Guttate Psoriasis: Results and Patient Assessment
Original Paper Dermatology 206;232:626 632 Received: December 6, 205 Accepted after revision: August 3, 206 Published online: November 25, 206 Phototherapy with Narrow-Band UVB in Adult Guttate Psoriasis:
More informationHorizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited
More informationTHE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS Mădălina FRÎNCU 1 Abstract: Biological
More informationPediatric Use: Safety and effectiveness of Ustekinumab (STELARA ) in pediatric patients have not been evaluated.
Original Issue Date (Created): January 1, 2010 Most Recent Review Date (Revised): January 28, 2014 Effective Date: April 1, 2014 I. POLICY Preauthorization Requirements for Ustekinumab (STELARA ) Note:
More informationPhototherapy for Psoriasis. Henry W. Lim, MD Chairman and C.S. Livingood Chair Department of Dermatology Henry Ford Hospital, Detroit, MI, USA
Phototherapy for Psoriasis Henry W. Lim, MD Chairman and C.S. Livingood Chair Department of Dermatology Henry Ford Hospital, Detroit, MI, USA Disclosure Investigator: Clinuvel Estée Lauder Ferndale Incyte
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20173283 Original Research Article A cross-sectional
More informationWhat is Cosentyx (secukinumab)?
What is Cosentyx (secukinumab)? Cosentyx is the first of a new class of medicines called interleukin- 17A (IL- 17A) inhibitors to be approved for the treatment of moderate- to- severe plaque psoriasis,
More informationCorporate Medical Policy
Corporate Medical Policy Light Therapy for Dermatologic Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: light_therapy_for_dermatologic_conditions 5/2012 11/2017 11/2018
More informationPsoriasis. Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement
Psoriasis Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement Copyright 2017 by Sea Courses Inc. All rights reserved. No part
More informationTherapeutic Management of Early Cutaneous Mycosis Fungoides
Therapeutic Management of Early Cutaneous Mycosis Fungoides L Frank Glass, MD Cutaneous Lymphoma Programs H Lee Moffitt Cancer Center and Research Institute George Washington University Dermatology and
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More informationUstekinumab for severe treatment-resistant psoriasis: a 24-week pilot study in Hong Kong Chinese
Hong Kong J. Dermatol. Venereol. (2011) 19, 59-64 Original Article Ustekinumab for severe treatment-resistant psoriasis: a 24-week pilot study in Hong Kong Chinese Ustekinumab SKF Loo, KH Lau, KM Ho Introduction:
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationUstekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases
Published online: September 26, 2013 1662 6567/13/0053 0254$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC)
More informationPUVA: Shall we still use it for psoriasis in 2019?
PUVA: Shall we still use it for psoriasis in 2019? Ben Stoff MD, MA Associate Professor Emory Department of Dermatology Phototherapy: F003 March 1, 2019 DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY
More informationDevelopments in Psoriasis Management Celgene Corporation 07/14 USII-CELG140030
Developments in Psoriasis Management 2014 Celgene Corporation 07/14 USII-CELG140030 Psoriasis (PsO) Is a Chronic Inflammatory Disease That Can Impact Patients Health-Related Quality of Life PsO is a chronic
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationWhat is Enbrel? Key features
What is Enbrel? Enbrel (also known by its generic name etanercept) is a biologic medication approved in April 2004 by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe
More informationUSTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE
Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA 36187 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of psoriatic arthritis (PsA)
More informationA Vitiligo Update for Pharmacists: Current Practices and Future Advances
A Vitiligo Update for Pharmacists: Current Practices and Future Advances Dalal Hammoudi Halat, RPh, MSc, PhD Assistant Professor School of Pharmacy, Lebanese International University Disclosure Dalal Hammoudi
More informationEXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS
EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS ACTIVITY 1: EARLY COLLABORATION IN THE TREATMENT OF PSA Key Slides COMMON COMORBIDITIES OF PSORIATIC DISEASE
More informationRegulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.27 Subject: Enbrel Page: 1 of 8 Last Review Date: March 16, 2018 Enbrel Description Enbrel (etanercept),
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Dimethyl fumarate for treating moderate to severe Draft scope (pre-referral) Draft remit/appraisal objective To appraise
More informationPsoriasis is a common inherited papulosquamous
PEDIATRIC DERMATOLOGY Series Editor: Camila K. Janniger, MD Infantile Psoriasis Camila K. Janniger, MD; Robert A. Schwartz, MD, MPH; Maria Letizia Musumeci, MD, PhD; Aurora Tedeschi, MD; Barbara Mirona,
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationIs Apremilast (Otezla) Effective in Reducing Pruritus in Adults over 18 Years Old with Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 3-2017 Is Apremilast (Otezla) Effective in
More informationDERMATOLOGY. The Changing Landscape of Psoriasis Treatment ABSTRACT
WHITE PAPER PRESENTED BY PREMIER RESEARCH The Changing Landscape of Psoriasis Treatment ABSTRACT Over the past two decades, biologic therapies have revolutionized the treatment of psoriasis, with more
More informationHorizon Scanning Centre March Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209
Horizon Scanning Centre March 2015 Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209 This briefing is based on information available at the time of research and a limited
More informationCertolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
NIHR Innovation Observatory Evidence Briefing: April 2017 Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112 LAY SUMMARY Plaque psoriasis is the most
More informationA systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C
A systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C Authors' objectives To compare the effectiveness of currently available treatments
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2104-4 Program Prior Authorization/Medical Necessity Medication Taltz (ixekizumab) P&T Approval Date 8/2016, 5/2017, 2/2018 Effective
More informationBioavailability 55% - 77%
Brand Name: Cosentyx Generic Name: secukinumab Manufacturer 1 : Novartis Pharmaceuticals Corporation Drug Class 2,3 : Antipsoriatic Agent, Interleukin-17A Receptor Antagonist Uses: Labeled Uses 1,2,3 :
More informationSystemic Treatment of Pediatric Psoriasis: A Review
DOI 10.1007/s13555-016-0117-6 REVIEW Systemic Treatment of Pediatric Psoriasis: A Review Maddalena Napolitano. Matteo Megna. Anna Balato. Fabio Ayala. Serena Lembo. Alessia Villani. Nicola Balato Received:
More information(ASO) 17. ( Antistreptolysin o) Downloaded from jmj.jums.ac.ir at 20: on Friday March 22nd 2019 [ DOI: /jmj.2.2.
(ASO) * : :... : 22 2 7. ( Antistreptolysin o) 2... : (%50). TODD 250 (%63/63) 22 4 200. 2.(P
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ustekinumab_stelara 02/2010 10/2018 10/2019 10/2018 Description of Procedure or Service Plaque psoriasis
More informationTopical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar
Topical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar Dr. Steven Feldman 1 Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
More informationPhotochemotherapy MM /09/2004. HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service: Home; Office
Photochemotherapy Policy Number: Original Effective Date: MM.02.015 11/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service:
More informationMonth/Year of Review: January 2015 Date of Last Review: January 2010
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationClinico-epidemiological profile, including body mass index of Malaysian children with psoriasis
ORIGINAL ARTICLE Clinico-epidemiological profile, including body mass index of Malaysian children with psoriasis Siew Eng Choon, FRCP, Chin Fang Ngim, MRCP, Premaa Supramaniam, BSc, Kwee Eng Tey, MRCP,
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationPrevalence of pruritus in psoriatic skin lesions and its relations to different variables
Original Article Prevalence of pruritus in psoriatic skin lesions and its relations to different variables Satyendra Kumar Singh Department of Dermatology & Venereology, Institute of Medical Sciences,
More informationEvaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationLOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS
Locally Available Biologic Agents in the Treatment of Psoriatic Arthritis 253 Phil. J. Internal Medicine, 47: 253-259, Nov.-Dec., 2009 LOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS
More information